REAL LIFE TREATMENT DURATION OF SORAFENIB OR SUNITINIB IN FIRST LINE METASTATIC RENAL CELL CARCINOMA PATIENTS-A COMPARATIVE ANALYSIS

被引：0
|
作者：
Hammerman, A. [1 ]
Klang, S. H. [1 ]
Liebermann, N. [1 ]
机构：
[1] Clalit Hlth Serv, Tel Aviv, Israel
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74272-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A260 / A260
页数：1
相关论文
共 50 条
  • [31] ECONOMIC EVALUATION OF SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN COLOMBIA
    Prieto, V. A.
    Reyes, J. M.
    Lopez-Cabra, C.
    Diaz, J. A.
    Urrego-Novoa, J. R.
    VALUE IN HEALTH, 2016, 19 (03) : A149 - A149
  • [32] Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    Remak, Edit
    Charbonneau, Claudie
    Negrier, Sylvie
    Kim, Sindy T.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) : 3995 - 4000
  • [33] Economic evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma in Mexico
    Emilio, Mucino-Ortega
    Joaquin Federico, Mould-Quevedo
    GACETA MEXICANA DE ONCOLOGIA, 2010, 9 (02): : 48 - 57
  • [34] predictive biomarkers for treatment selection of sorafenib or sunitinib in metastatic renal cell carcinoma.
    Naito, Sei
    Bilim, Vladimir
    Tsuchiya, Norihiko
    Tomita, Yoshihiko
    CANCER SCIENCE, 2021, 112 : 509 - 509
  • [35] Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
    Hansen, Caroline Randrup
    Grimm, Daniela
    Bauer, Johann
    Wehland, Markus
    Magnusson, Nils E.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (02)
  • [36] Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma
    Qin, Shu-Kui
    Jin, Jie
    Guo, Jun
    Wang, Jin-Wan
    Zhou, Fang-Dian
    Huang, Yi-Ran
    Ren, Xiu-Bao
    Ye, Ding-Wei
    Pan, Sharon
    Sajben, Peter
    Wang, Qiao
    FUTURE ONCOLOGY, 2018, 14 (18) : 1835 - 1845
  • [37] Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis
    Li, Dailong
    Wan, Sha
    Li, Wanqiang
    Cheng, Chunlai
    Xu, Lu
    Gu, Peng
    MEDICINE, 2023, 102 (36) : E34983
  • [38] Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma
    Mego, M.
    Reckova, M.
    Obertova, J.
    Sycova-Mila, Z.
    Brozmanova, K.
    Mardiak, J.
    ANNALS OF ONCOLOGY, 2007, 18 (11) : 1906 - 1907
  • [39] Sorafenib and sunitinib for elderly patients with renal cell carcinoma
    Miled, Olfa Derbel
    Dionne, Christine
    Terret, Catherine
    Segura-Ferlay, Celine
    Flechon, Aude
    Neidhart, Eve-Marie
    Negrier, Sylvie
    Droz, Jean-Pierre
    JOURNAL OF GERIATRIC ONCOLOGY, 2013, 4 (03) : 255 - 261
  • [40] SUNITINIB AND SORAFENIB THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (mRCC): SAFETY PROFILE
    Massari, Francesco
    Cricca, Antonia
    Sperandi, Francesca
    Martoni, Andrea Angelo
    ANTICANCER RESEARCH, 2010, 30 (04) : 1379 - 1380
12345